V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 330012664 | 330003797 | 1.79 | 54.2 | Palliative (P) | 2017-12-23 | 2018-06-23 | EW EuroEwing 2012 Arm A VAI | N | null | 330007378 | TRIAL |
| 330012665 | 330003810 | 0 | 33.5 | Adjuvant (A) | 2015-04-04 | 2015-04-06 | OST Euramos 1 Closed Trial - IE | Y | null | 330007427 | TRIAL |
| 330012666 | 330003814 | null | 133 | Palliative (P) | 2017-01-29 | 2017-02-15 | Trial Unspecified | N | null | 330007452 | TRIAL |
| 330012667 | 330011657 | 1.79 | 71 | Curative (C) | 2015-02-25 | 2015-08-17 | Trial Unspecified | 1 | N | 330007479 | TRIAL |
| 330012668 | 330003842 | 1.61 | 47 | Curative (C) | 2014-09-04 | 2014-09-04 | DOXORUBICIN | N | Y | 330007542 | DOXORUBICIN |
| 330012669 | 330003869 | 1.75 | 88 | Adjuvant (A) | 2017-10-20 | 2017-10-20 | Trial Unspecified | null | null | 330007616 | TRIAL |
| 330012670 | 330003872 | 1.58 | null | Curative (C) | 2015-10-24 | 2015-11-03 | Trial Unspecified | Y | N | 330007623 | TRIAL |
| 330012671 | 330003886 | 1.74 | 86.95 | Neo-adjuvant (N) | 2015-02-04 | 2015-10-25 | Methotrexate Intermed dose (1g/m2) | 1 | N | 330007676 | METHOTREXATE |
| 330012672 | 330008110 | 1.82 | 75.4 | Palliative (P) | null | 2015-05-05 | DOXORUBICIN | Y | null | 330007703 | DOXORUBICIN |
| 330012673 | 330008112 | 1.83 | 61.4 | Curative (C) | 2013-05-09 | 2013-06-20 | Cisplatin 7 day | N | N | 330007719 | CISPLATIN |
| 330012674 | 330003896 | null | 97.1 | Adjuvant (A) | null | 2016-11-13 | MIFAMURTIDE | Y | null | 330007724 | MIFAMURTIDE |
| 330012675 | 330003905 | 0 | 81 | Curative (C) | 2017-10-19 | 2017-11-07 | Trial Unspecified | N | null | 330007739 | TRIAL |
| 330012676 | 330003910 | 1.79 | 52.05 | Palliative (P) | 2016-08-24 | 2017-03-14 | METHOTREXATE | N | Y | 330007754 | METHOTREXATE |
| 330012677 | 330011675 | 1.68 | 64.3 | Curative (C) | 2018-04-04 | 2018-04-21 | Cisplatin | null | N | 330007879 | CISPLATIN |
| 330012678 | 330003930 | 1.6 | 27.7 | Curative (C) | 2017-01-26 | 2017-02-09 | EW EuroEwing 2012 Arm A VAI | N | N | 330007899 | TRIAL |
| 330012679 | 330003936 | 1.8 | 45.5 | Not known (9) | 2017-12-02 | 2018-04-17 | MIFAMURTIDE | 2 | N | 330007924 | MIFAMURTIDE |
| 330012680 | 330003938 | 0 | null | Palliative (P) | 2017-12-14 | 2018-03-04 | METHOTREXATE | N | N | 330007962 | METHOTREXATE |
| 330012681 | 330003942 | 1.75 | null | Palliative (P) | 2014-08-20 | 2014-08-20 | EW EuroEwing 2012 Arm B IE | N | N | 330007971 | TRIAL |
| 330012682 | 330003949 | 1.7 | null | Curative (C) | 2014-07-31 | 2015-01-02 | Rituximab | null | N | 330007988 | RITUXIMAB |
| 330012683 | 330003955 | 0 | 72 | Curative (C) | 2017-04-28 | 2017-05-03 | Rituximab (Maintenance) | 02 | N | 330008037 | RITUXIMAB |
| 330012684 | 330003961 | 0 | 90 | Neo-adjuvant (N) | 2018-12-10 | 2018-12-11 | OST Euramos 1 Closed Trial - AP | N | N | 330008049 | MAP |
| 330012685 | 330012388 | 2 | null | Curative (C) | 2015-02-04 | 2015-02-18 | Etoposide + Ifosfamide (3 days) | null | null | 330008090 | ETOPOSIDE + IFOSFAMIDE |
| 330012686 | 330010436 | 1.7 | 52 | Neo-adjuvant (N) | 2014-02-13 | 2014-03-11 | Cetuximab 7 day (>Cycle 2) | N | N | 330008138 | CETUXIMAB |
| 330012687 | 330003999 | 1.64 | 58.3 | Curative (C) | 2016-03-10 | 2016-04-18 | OST Euramos 1 Closed Trial - AP | N | Y | 330008194 | MAP |
| 330012688 | 330004006 | 0 | 54 | Curative (C) | 2016-11-08 | 2016-11-09 | Etoposide + Ifosfamide (3 days) | N | N | 330008198 | ETOPOSIDE + IFOSFAMIDE |
| 330012689 | 330004016 | 1.68 | 54.3 | Curative (C) | 2017-09-23 | 2017-11-03 | Cisplatin +Fluorouracil (2 wk) | 02 | N | 330008235 | CISPLATIN + FLUOROURACIL |
| 330012690 | 330004027 | 1.66 | null | Palliative (P) | 2017-05-02 | 2017-09-10 | ETOPOSIDE + IFOSFAMIDE | N | N | 330008284 | ETOPOSIDE + IFOSFAMIDE |
| 330012691 | 330004044 | 1.68 | 54.8 | Palliative (P) | 2017-10-28 | 2017-11-22 | Etoposide + Ifosfamide (3 days) | N | N | 330008370 | ETOPOSIDE + IFOSFAMIDE |
| 330012692 | 330004050 | 1.8 | 87.8 | Curative (C) | 2017-01-09 | 2017-01-09 | MAP | N | N | 330008382 | MAP |
| 330012693 | 330004057 | 1.68 | 66.6 | Palliative (P) | 2016-05-04 | 2016-11-30 | Rituximab (SUBCUTANEOUS Maintenance) | N | Y | 330008395 | RITUXIMAB |
| 330012694 | 330004073 | 1.55 | 96.7 | Curative (C) | 2018-05-09 | 2018-06-08 | CETUXIMAB | 02 | Y | 330008566 | CETUXIMAB |
| 330012695 | 330004082 | 1.78 | null | Neo-adjuvant (N) | 2015-06-16 | 2015-12-08 | PAM x 2 pre-surgery (cycles 1&2) | N | N | 330008614 | MAP |
| 330012696 | 330004107 | 1.75 | 55.8 | Curative (C) | 2016-11-06 | 2016-11-08 | OST Euramos 1 Closed Trial - AP | 2 | N | 330008905 | MAP |
| 330012698 | 330004118 | 0 | 92.7 | Neo-adjuvant (N) | 2018-03-28 | 2018-05-03 | Docetaxel+Gemcitabine (no prior RT) | N | null | 330008951 | DOCETAXEL + GEMCITABINE |
| 330012699 | 330004124 | 1.6 | null | Palliative (P) | 2018-06-28 | 2018-07-26 | PAM x 2 pre-surgery (cycles 1&2) | 02 | N | 330008977 | MAP |
| 330012700 | 330004130 | 0 | null | Palliative (P) | 2014-12-02 | 2014-12-02 | OST Euramos 1 Closed Trial - M | 02 | null | 330009031 | METHOTREXATE HIGH DOSE |
| 330012702 | 330004144 | 1.78 | null | Not known (9) | 2015-05-03 | 2015-06-15 | MAP | Y | N | 330009101 | MAP |
| 330012703 | 330010485 | 0 | 27.5 | Curative (C) | 2017-09-22 | 2017-09-25 | Docetaxel + Gemcitabine (prior RT) | null | null | 330009184 | DOCETAXEL + GEMCITABINE |
| 330012704 | 330004172 | 1.81 | 68 | Palliative (P) | 2013-05-05 | 2013-06-21 | CETUXIMAB | N | N | 330009253 | CETUXIMAB |
| 330012707 | 330004208 | null | 77.5 | Curative (C) | 2018-07-28 | 2018-07-28 | Carboplatin AUC 6 - 10 | N | N | 330009744 | CARBOPLATIN |
| 330012708 | 330004213 | null | 70.7 | Not known (9) | 2017-12-03 | 2018-03-02 | OST Euramos 1 Closed Trial - AP | N | Y | 330009753 | MAP |
| 330012709 | 330004217 | 1.63 | null | Palliative (P) | 2015-07-06 | 2015-10-09 | Rituximab (Maintenance) | N | N | 330009847 | RITUXIMAB |
| 330012711 | 330004243 | 1.8 | 47.9 | Curative (C) | 2017-05-30 | 2017-05-30 | Carboplatin AUC 2 - 5 | N | N | 330010672 | CARBOPLATIN |
| 330012712 | 330004249 | 1.59 | 0 | Palliative (P) | 2014-09-12 | 2014-09-27 | CETUXIMAB | N | N | 330010701 | CETUXIMAB |
| 330012713 | 330004251 | 1.76 | 83.4 | Curative (C) | 2015-07-06 | 2015-07-09 | CARBOPLATIN | N | N | 330010712 | CARBOPLATIN |
| 330012714 | 330008328 | 1.67 | 87.8 | Adjuvant (A) | 2018-10-09 | 2018-10-09 | PAM x 2 post-surgery (cycles 3&4) | N | N | 330010739 | MAP |
| 330012715 | 330004264 | 1.45 | 24 | Palliative (P) | 2016-07-14 | 2016-07-14 | ETOPOSIDE + IFOSFAMIDE | 02 | N | 330010873 | ETOPOSIDE + IFOSFAMIDE |
| 330012716 | 330004272 | 1.64 | 108 | Curative (C) | 2018-07-17 | 2018-07-17 | Rituximab (Maintenance) | 02 | N | 330010902 | RITUXIMAB |
| 330012717 | 330004278 | 1.7 | 78.2 | Curative (C) | null | 2018-09-29 | Carboplatin AUC 6 - 10 | N | N | 330010929 | CARBOPLATIN |
| 330012718 | 330010523 | 1.75 | 51 | Curative (C) | 2016-12-08 | 2016-12-29 | Rituximab | N | N | 330010974 | RITUXIMAB |